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COMMENTARY
Coagulopathy following major trauma
hemorrhage: lytic, lethal and a lack of fibrinogen
Ross Davenport
See related research by Oshiro et al., http://ccforum.com/content/18/2/R61
Abstract
Trauma-induced coagulopathy (TIC) is present soon
after injury and is associated with increased
transfusion requirements and worse outcomes. The
pathophysiological mechanisms, which result in the
widespread derangements of hemostasis following
major trauma hemorrhage, are as yet not fully
defined. Profound activation of fibrinolytic pathways
and fibrinogen depletion appear to be fundamental
processes in the development of TIC and offer potential
therapeutic targets. Collaborative and multi-disciplinary
scientific study is thus a research priority in order to
characterize the primary drivers of TIC and develop
targeted and efficacious treatment strategies.
Trauma-induced coagulopathy (TIC) exacerbates bleeding
after severe injury and is associated with poor outcomes.
In the previous issue of Critical Care, Oshiro and col-
leagues [1] showed that changes in hemostatic competency
occur early following trauma and are described by a pro-
found derangement in coagulation, in particular massive
activation of fibrinolysis and potentially fibrinogenolysis. In
the context of the CRASH-2 (Clinical Randomization of an
Antifibrinolytic in Significant Hemorrhage 2) trial [2], which
showed a mortality benefit with the use of the anti-
fibrinolytic tranexamic acid (TXA) in trauma hemorrhage,
this work further highlights the pathophysiological impor-
tance of fibrinolysis in TIC. Early detection of clotting defi-
ciencies appears to have prognostic value, and the authors
provide evidence for the utility of a scoring system in
predicting outcome and transfusion need [1]. However, a
definitive mechanism for TIC and thus optimal thera-
peutic interventions are currently unknown. Investigation
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of pathophysiological pathways and identification of effica-
cious, targeted treatment strategies therefore remain a re-
search priority.
Mechanistic understanding of acute hypocoagulability
and early hypercoagulability following major trauma in
recent years has moved away from the simplistic and re-
ductionist theories of the lethal triad (hypothermia, dilu-
tion, and acidosis). The cell-based model of hemostasis,
an intimate relationship between coagulation and in-
flammation, platelet function, fibrinogen availability, and
importance of the endothelium have shaped current hy-
potheses implicating tissue hypoperfusion and tissue
trauma as potential drivers for TIC [3]. In a large pro-
spective study of trauma patients, with serial blood sam-
pling, Oshiro and colleagues have reaffirmed the presence
of an early coagulopathy of trauma and have shown it to
be defined predominantly by a fibrinolytic phenotype with
increased fibrinogen breakdown [1]. Through application
of the Japanese Association for Acute Medicine dissemi-
nated intravascular coagulation scoring system obtained
immediately after arrival, the authors have demonstrated a
close association with an alternative definition of post-
traumatic clotting derangement: acute coagulopathy of
trauma shock. In addition, the scoring system used has
been shown to be an independent predictor of prognosis
and the need for massive transfusion.
Unfortunately, historical definitions and difficulties in
reaching consensus on nomenclature to describe early co-
agulation changes in trauma have prohibited any quantum
leaps in our understanding of the disease process. Scoring
systems in trauma and coagulation are numerous yet
function only as surrogates for disease-specific markers.
Global collaboration and coordinated study by hematolo-
gists, experts in transfusion medicine, trauma surgeons,
and critical care physicians are required for a comprehen-
sive scientific investigation of TIC. Both European and US
collaborations appear to have answered this call to arms
with two large-scale research initiatives both entitled
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Action for Curing TIC [4] and the US Trans-Agency
Research Consortium for TIC [5]. The objectives of both
collaborations are to support multi-component scientific
research to conduct hypothesis-driven studies of TIC, link
clinical investigators with basic scientists, and fund
trauma-related clinical trials of TIC.
Recent years have seen a handful of large international
clinical trials of TXA (CRASH-2) [2], recombinant Fac-
tor VIIa [6], and fresh frozen plasma (FFP)/platelets
(Pragmatic Randomized Optimal Platelet and Plasma
Ratios, or PROPPR) [7] founded on a limited mechanis-
tic understanding of TIC. However, among researchers
there is a growing consensus, supported by the study by
Oshiro and colleagues [1], that both fibrinogen availability
and inhibition of fibrinolysis are essential components for
hemostasis. Evidence from the trauma community, sup-
ported by basic science and research in other disciplines
in which major hemorrhage is a frequent occurrence (that
is, cardiac surgery and obstetrics), has reached broad
agreement of the necessity to maintain fibrinogen at more
than 1.5 g/L [8]. Studies have shown it falls fastest and
most significantly during trauma hemorrhage [9,10] com-
pared with other clotting factors. More importantly,
fibrinogen supplementation with either cryoprecipitate
(UK or US) or fibrinogen concentrate (Europe) is often
delayed or considered second-line in the empiric delivery
of hemostatic coagulation therapy and therefore replace-
ment fails to keep up with depletion. Consequently, early-
and high-dose fibrinogen replacement is the subject of
two pilot randomized controlled trials in the UK (Early
Cryoprecipitate for Severe Trauma Haemorrhage Trial, or
CRYOSTAT) [11] and Austria (Fibrinogen Concentrate in
Trauma Patients, Presumed to Bleed, or FiTIC) [12] due
to report later this year.
In agreement with Oshiro and colleagues [1], previous
observational studies have shown a high prevalence of fi-
brinolytic activation after major trauma [13,14], but doubt
remains as to the best method of rapid detection.
Currently, viscoelastic hemostasis assays - for example,
thromboelastography or rotational thromboelastometry -
are the only point-of-care measures which can detect fi-
brinolysis, although both are relatively insensitive mea-
sures of clot breakdown. However, CRASH-2 [2] and the
large body of evidence from both elective and emergency
surgery have shown TXA to be a safe and efficacious
treatment for hemorrhage without assay-proven evidence
of fibrinolysis. The mechanism of fibrinogen depletion is
unclear, and fibrinogen cleavage by plasmin is difficult to
measure, although hypothetically direct fibrinogenolysis
may explain the rapid and significant loss of fibrinogen
during massive activation of fibrinolytic pathways.
In this study, Oshiro and colleagues [1] have demon-
strated the importance of fibrinolysis and potentially
fibrinogenolysis in the pathogenesis of early traumatic
coagulopathy. However, further work is required to fully
delineate early coagulopathy following major trauma to
achieve a better understanding of the mechanistic drivers
and develop targeted treatment strategies. Empiric trans-
fusion algorithms do not improve TIC during active
hemorrhage [15], and the efficacy of FFP is unclear. Early
treatment with TXA is associated with mortality benefit in
trauma hemorrhage, and early fibrinogen replacement
could potentially augment correction of TIC, reduce
transfusion requirements, and improve outcomes. The
challenge remains to determine how best to stratify those
at risk of major bleeding and which patients are most
likely to benefit from early treatment. Coordinated, cross-
disciplinary efforts at unraveling the complexities of the
coagulation system are required to best identify thera-
peutic targets and improve outcomes from major trauma
hemorrhage.
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